Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 10 Neoplasms 6 Lung Neoplasms 4 Colorectal Neoplasms 3 Neoplasm Metastasis 2 Melanoma 2 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Ovarian Neoplasms 1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Mesothelioma, Malignant 1 Mesothelioma 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Neuroendocrine 1 Breast Neoplasms 1

Interventions

Pemetrexed 40 Cisplatin 35 pembrolizumab 21 Nivolumab 17 Carboplatin 16 Ipilimumab 13 Gemcitabine 10 Cyclophosphamide 9 fludarabine 6 durvalumab 6 Bevacizumab 6 Radiotherapy, Intensity-Modulated 4 LMB-100 4 Drug Therapy 4 Dexamethasone 4 tremelimumab 3 tazemetostat 3 spartalizumab 3 olaparib 3 niraparib 3 atezolizumab 3 anetumab ravtansine 3 amatuximab 3 Vinorelbine 3 Paclitaxel 3 Oxaliplatin 3 Imatinib Mesylate 3 Fluorouracil 3 Cerebral Decortication 3 Blood Specimen Collection 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Mesothelioma × dostarlimab × Thoracic × Clear all

NCT04940637 2023-05-12

UNITO-001

University of Turin, Italy

Phase 2 Unknown

Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡